ROGI, would you mind to say that again? I didn't get it.
I think what is going on here is that when SGMO is editing CD4+ and CD8+ cells for autologous transplant, SGMO has come up with a method that makes the cell editing more efficient.
Is this patent only for autologous transplants?
Is this patent just efficiency of the autologous transplant?
You were saying that the patent involves culling some cells out during the ex-vivo bioreactor expansion. Presumably these cells are culled prior to the gene editing? I did not get why the cells are culled. What is it about these cells that makes them difficult to edit?
My last question, if you have the patience for another, is what are the "beads" about" and how is that an improvement on electroporation? My understanding of electroporation is that an electric field is applied to the cell culture which causes plasmids in solution with the cells to enter the cells through pores in the cell membrane created by the (pulsed or static?) electric field. I think that you like the "beads" system better. Is there a simple explanation about the beads? Maybe a tutorial article somewhere?
Thanks a lot in advance!